The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
It is the first autotaxin inhibitor to be investigated in cancer patients
Sharma joined the Morepen Lab in 2004
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Subscribe To Our Newsletter & Stay Updated
